A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers

Trial Profile

A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms Neo-Ava; NeoAva
  • Sponsors Roche; Sanofi
  • Most Recent Events

    • 09 May 2017 Primary endpoint (Pathological complete response (pCR) in breast and axillary nodes) has not been met.
    • 09 May 2017 Results (n=132) assessing predictive role of gene expression for identification of patients likely to be benefitted from bevacizumab combination therapy, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 20 Apr 2016 Results of reverse phase protein array(RPPA) proteomic analysis (n=132) were presented at the 107th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top